Non-Muscle Invasive Bladder Cancer: Difference between revisions
Urology4all (talk | contribs) |
Urology4all (talk | contribs) |
||
| Line 390: | Line 390: | ||
* 2016 International Bladder Cancer Group Definitions[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321095/table/T5/] | * 2016 International Bladder Cancer Group Definitions[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321095/table/T5/] | ||
# '''BCG-intolerant''' | # '''<span style="color:#009999">BCG-intolerant</span>''' | ||
#* '''Disease persistence as a result of inability to receive adequate BCG* because of toxicity.''' | #* '''Disease persistence as a result of inability to receive adequate BCG* because of toxicity.''' | ||
#**Adequate BCG is defined as at least 5-6 weekly instillations of an induction course followed by at least one maintenance cycle (consisting of at least 2 out of 3 weekly BCG treatments) or a second induction cycle (whereby at least 2 of 6 weekly instillations were received). | #**Adequate BCG is defined as at least 5-6 weekly instillations of an induction course followed by at least one maintenance cycle (consisting of at least 2 out of 3 weekly BCG treatments) or a second induction cycle (whereby at least 2 of 6 weekly instillations were received). | ||
# '''BCG-relapsing''' | # '''<span style="color:#009999">BCG-relapsing</span>''' | ||
#* '''Recurrence of high-grade disease after achieving a disease-free state at 6 months after adequate BCG.''' | #* '''Recurrence of high-grade disease after achieving a disease-free state at 6 months after adequate BCG.''' | ||
#**Sub-stratified into early (<12 months) vs. intermediate (12-24 months) vs. late (>24 months) | #**Sub-stratified into early (<12 months) vs. intermediate (12-24 months) vs. late (>24 months) | ||
#*** Prognosis improved with increasing duration of disease-free interval | #*** Prognosis improved with increasing duration of disease-free interval | ||
# '''BCG-refractory''' | # '''<span style="color:#009999">BCG-refractory</span>''' | ||
#* '''Persistent high-grade disease at 6 months despite adequate BCG treatment''' | #* '''Persistent high-grade disease at 6 months despite adequate BCG treatment''' | ||
#*'''Any stage or grade progression by 3 months after the first BCG cycle''' (eg. initial Ta/TaHG or CIS then 3 months BCG then T1HG) | #*'''Any stage or grade progression by 3 months after the first BCG cycle''' (eg. initial Ta/TaHG or CIS then 3 months BCG then T1HG) | ||
#** BCG-refractory patients are at increased risk of progression and worse 5-year survival rates when compared to patients with a complete response to induction therapy | #** BCG-refractory patients are at increased risk of progression and worse 5-year survival rates when compared to patients with a complete response to induction therapy | ||
# '''BCG-unresponsive''' | # '''<span style="color:#009999">BCG-unresponsive</span>''' | ||
#*'''Includes''' | #*'''Includes''' | ||
#**'''All BCG refractory tumours''' | #**'''All BCG refractory tumours''' | ||